Braveheart Bio to Participate in Stifel Virtual Cardiometabolic Forum

SAN FRANCISCO, Sept. 16, 2026 /CourierPR/ -- Braveheart Bio, a clinical-stage biopharmaceutical company focused on developing therapies for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, will participate in the Stifel Virtual Cardiometabolic Forum on September 30, 2026.

Braveheart Bio’s lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) designed for the treatment of both obstructive and non-obstructive HCM. The company aims to address the limitations of currently available CMIs by ensuring rapid onset, consistent depth of response, preservation of systolic function, prompt reversibility, and a straightforward approach to titration and monitoring.

The company’s focus on HCM and other serious cardiovascular diseases underscores its commitment to advancing therapeutic options for patients. By participating in the Stifel Virtual Cardiometabolic Forum, Braveheart Bio seeks to share insights and progress on its research and development efforts with the broader medical and investment communities.

The forum, organized by Stifel, is expected to attract a range of stakeholders, including healthcare professionals, investors, and industry experts, all of whom are interested in the latest advancements in cardiometabolic research. Braveheart Bio’s participation is seen as a significant step in its journey to bring innovative treatments to patients suffering from HCM and other related conditions.